Zobrazeno 1 - 5
of 5
pro vyhledávání: '"A Gili Marco"'
The role of galenic innovation in improving treatment compliance and persistence: three case studies
Publikováno v:
ClinicoEconomics and Outcomes Research, Vol 2011, Iss default, Pp 109-116 (2011)
York Zoellner1, Maria-Magdalena Balp2, Andrea Gili Marco21Hamburg University of Applied Sciences, Hamburg, Germany; 2Novartis Pharma AG, Basel, SwitzerlandBackground: The purpose of this study was to explore whether newer galenic formulations with lo
Externí odkaz:
https://doaj.org/article/5a9f659252b34ec0a4a36604714b72ca
Publikováno v:
ClinicoEconomics and Outcomes Research, Vol 2011, Iss default, Pp 187-188 (2011)
York Zoellner1, Maria-Magdalena Balp2, Andrea Gili Marco21Hamburg University of Applied Sciences, Hamburg, Germany; 2Novartis Pharma AG, Basel, SwitzerlandThe role of galenic innovation in improving treatment compliance and persistence: three case st
Externí odkaz:
https://doaj.org/article/c09b4937cade48c7ad80d506ee9da852
Publikováno v:
Respiratory medicine. 108(1)
Summary Omalizumab is an add-on therapy for patients with uncontrolled severe allergic asthma. In Europe, patients must fulfil a number of additional criteria to become eligible for omalizumab therapy, creating a challenge for epidemiology studies to
Publikováno v:
Pneumologie. 66
The role of galenic innovation in improving treatment compliance and persistence: three case studies
Publikováno v:
ClinicoEconomics and Outcomes Research: CEOR
York Zoellner1, Maria-Magdalena Balp2, Andrea Gili Marco21Hamburg University of Applied Sciences, Hamburg, Germany; 2Novartis Pharma AG, Basel, SwitzerlandBackground: The purpose of this study was to explore whether newer galenic formulations with lo